Analysis

COVID-19 A data perspective

COVID-19: A data perspective: Explore key economic trends and social challenges that arise as the COVID-19 situation evolves.

Filter results by

Search Help
Currently selected filters that can be removed

Keyword(s)

Year of publication

3 facets displayed. 0 facets selected.

Author(s)

3 facets displayed. 0 facets selected.
Sort Help
entries

Results

All (5)

All (5) ((5 results))

  • Articles and reports: 88F0006X2003013
    Description:

    This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.

    Release date: 2003-12-08

  • Articles and reports: 88-003-X20030026561
    Geography: Canada
    Description:

    Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.

    Release date: 2003-06-27

  • Articles and reports: 88-003-X20030026570
    Geography: Canada
    Description:

    In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?

    Release date: 2003-06-27

  • Articles and reports: 88-003-X20020016152
    Geography: Canada
    Description:

    The Biotechnology Use & Development Survey-1999 provides insights into the transition from R&D to the commercial use of a technology in products and processes. Improvement in product quality is reported as the number one benefit derived from using biotechnologies. This article explores some of the characteristics of the firms that use biotechnologies addressing the questions: "Why use biotechnology?" and "Why not use biotechnology?"

    Release date: 2002-02-15

  • Articles and reports: 88-003-X20000035772
    Geography: Canada
    Description:

    Technological change and innovations depend greatly on R&D activities and investments. R&D is concentrated around the "core firms" that are responsible for 87% of expenditures. Biotechnology R&D performers accounted for $904 million of R&D expenditure. Biotechnology R&D is concentrated in large firms with 75% of R&D occuring in firms with 100 or more employees. Almost 77% of funding sources for R&D in biotechnology came from the private sector and 21% from foreign sources.

    Release date: 2000-10-06
Stats in brief (0)

Stats in brief (0) (0 results)

No content available at this time.

Articles and reports (5)

Articles and reports (5) ((5 results))

  • Articles and reports: 88F0006X2003013
    Description:

    This paper used data from the 2001 Biotechnology Use and Development Survey (BUDS) to look into bioproduct development using biotechnologies. Results show that the development of bioproducts has become an intrinsic part of the activities of Canadian biotechnology firms.

    Release date: 2003-12-08

  • Articles and reports: 88-003-X20030026561
    Geography: Canada
    Description:

    Nanotechnology is an emerging technology. Has it reached the point that warrants the development of a comprehensive statistical measurement program? If so, what indicators should be used? Major spending initiatives in nanotechnology investing are currently underway. There is precedence for using developed methods and techniques to address the questions 'who,' 'what,' 'where' and 'why.' Statistics Canada's experience may be invaluable in the development of a nanotechnology statistical program.

    Release date: 2003-06-27

  • Articles and reports: 88-003-X20030026570
    Geography: Canada
    Description:

    In 2001, Canadian biotech firms raised $980 million in financing capital, a sharp drop from the $2.1 billion raised in 1999. Overall, 114 firms out of 188 (61%) that attempted to raise capital either failed or did not reach their targets. Why are biotech firms encountering difficulties in raising financing capital?

    Release date: 2003-06-27

  • Articles and reports: 88-003-X20020016152
    Geography: Canada
    Description:

    The Biotechnology Use & Development Survey-1999 provides insights into the transition from R&D to the commercial use of a technology in products and processes. Improvement in product quality is reported as the number one benefit derived from using biotechnologies. This article explores some of the characteristics of the firms that use biotechnologies addressing the questions: "Why use biotechnology?" and "Why not use biotechnology?"

    Release date: 2002-02-15

  • Articles and reports: 88-003-X20000035772
    Geography: Canada
    Description:

    Technological change and innovations depend greatly on R&D activities and investments. R&D is concentrated around the "core firms" that are responsible for 87% of expenditures. Biotechnology R&D performers accounted for $904 million of R&D expenditure. Biotechnology R&D is concentrated in large firms with 75% of R&D occuring in firms with 100 or more employees. Almost 77% of funding sources for R&D in biotechnology came from the private sector and 21% from foreign sources.

    Release date: 2000-10-06
Journals and periodicals (0)

Journals and periodicals (0) (0 results)

No content available at this time.

Date modified: